Association between the MTHFR C677T polymorphism and risk of cancer: evidence from 446 case–control studies

Tumor Biology

Volumn 36, Issue 11, 2015, Pages 8953-8972

  Xie, Shu Zhe ^a   Liu, Zhi Zhong ^b   Yu, Jun hua ^c   Liu, Li ^d   Wang, Wei ^b   Xie, Dao Lin ^a   Qin, Jiang Bo ^a  

^a CHANGZHI MEDICAL COLLEGE   (China)

^b ZHUHAI PEOPLE S HOSPITAL ZHUHAI HOSPITAL AFFILIATED WITH JINAN UNIVERSITY   (China)

^c Central Hospital of Ezhou   (China)

^d TIANJIN FIRST CENTRAL HOSPITAL   (China)

Author keywords

Cancer; Meta analysis; MTHFR; Polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYTOSINE; THYMINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MTHFR PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; ASIAN; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; COLON CANCER; COLORECTAL CANCER; ETHNICITY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; INDIAN; LUNG CANCER; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RISK ASSESSMENT; SEX DIFFERENCE; STOMACH CANCER; ALLELE; CLASSIFICATION; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; META ANALYSIS; NEOPLASM; PATHOLOGY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84949106357     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3648-z     Document Type: Article

References (34)

1. Kwasniewska A, Tukendorf A, Semczuk M. Folate deficiency and cervical intraepithelial neoplasia. Eur J Gynaecol Oncol. 1997;18:526–30.
2. Eichholzer M, Luthy J, Moser U, Fowler B. Folate and the risk of colorectal, breast and cervix cancer: the epidemiological evidence. Swiss Med Wkly. 2001;131:539–49.
3. Fodinger M, Horl WH, Sunder-Plassmann G. Molecularbiology of 5,10-methylenetetrahydrofolate reductase. J Nephrol. 2000;13:20–33.
4. Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab. 2000;71:121–38.
5. Lucock M. Is folic acid the ultimate functional food component for disease prevention? BMJ. 2004;328:211–4.
6. Cicek MS, Nock NL, Li L, Conti DV, Casey G, Witte JS. Relationship between methylenetetrahydrofolate reductase C677T and A1298C genotypes and haplotypes and prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev. 2004;13:1331–6.
7. García-Closas R, García-Closas M, Kogevinas M, Malats N, Silverman D, Serra C, et al. Food, nutrient and heterocyclic amine intake and the risk of bladder cancer. Eur J Cancer. 2007;43:1731–40.
8. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–3.
9. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996;93:7–9.
10. Friso S, Choi SW. Gene-nutrient interactions in one-carbon metabolism. Curr Drug Metab. 2005;6:37–46.
11. Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost. 1997;78:523–6.
12. Niu YM, Deng MH, Chen W, Zeng XT, Luo J. MTHFR C677T gene polymorphism and head and neck cancer risk: a meta-analysis based on 23 publications. Dis Markers. 2015;2015:681313.
13. Macis D, Maisonneuve P, Johansson H, Bonanni B, Botteri E, Iodice S, et al. Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case–control study and a pooled meta-analysis. Breast Cancer Res Treat. 2007;106:263–71.
14. Li K, Li W, Dong X. Association of 677 C>T (rs1801133) and 1298 A>C (rs1801131) polymorphisms in the MTHFR gene and breast cancer susceptibility: a meta-analysis based on 57 individual studies. PLoS One. 2014;9, e71290.
15. Liu YX, Wang B, Wan MH, Tang WF, Huang FK, Li C. Meta-analysis of the relationship between the metholenetetrahydrofolate reductase C677T genetic polymorphism, folate intake and esophageal cancer. Asian Pac J Cancer Prev. 2011;12:247–52.
16. Fang Y, Xiao F, An Z, Hao L. Systematic review on the relationship between genetic polymorphisms of methylenetetrahydrofolate reductase and esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 2011;12:1861–6.
17. Xia LZ, Liu Y, Xu XZ, Jiang PC, Ma G, Bu XF, et al. Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer susceptibility. World J Gastroenterol. 2014;20:11429–38.
18. Ramsey SD, Holmes RS, McDermott CL, Blough DK, Petrin KL, Poole EM, et al. A comparison of approaches for association studies of polymorphisms and colorectal cancer risk. Colorectal Dis. 2012;14:e573–86.
19. Hubner RA, Houlston RS. MTHFR C677T and colorectal cancer risk: a meta-analysis of 25 populations. Int J Cancer. 2007;120:1027–35.
20. Wang X, Yue K, Hao L. Meta-analysis of methylenetetrahydrofolate reductase polymorphism and lung cancer risk in Chinese. Int J Clin Exp Med. 2015;8:1521–5.
21. Tang M, Wang SQ, Liu BJ, Cao Q, Li BJ, Li PC, et al. The methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and tumor risk: evidence from 134 case–control studies. Mol Biol Rep. 2014;41:4659–73.
22. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol. 2002;156:300–10.
23. Davey SG, Egger M. Meta-analyses of randomized controlled trials. Lancet. 1997;350:1182.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. Br Med J. 2003;327:557–60.
25. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Natl Cancer Inst. 1959;22:719–48.
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
27. Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, et al. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 2009;10:772–84.
28. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.
29. Egger M, Smith DG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315:629–34.
30. Friedman G, Goldschmidt N, Friedlander Y, Ben-Yehuda A, Selhub J, Babaey S, et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. J Nutr. 1999;129:1656–61.
31. Parle-McDermott A, Mills JL, Molloy AM, Carroll N, Kirke PN, Cox C, et al. The MTHFR 1298CC and 677TT genotypes have opposite associations with red cell folate levels. Mol Genet Metab. 2006;88:290–4.
32. Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull. 1999;55:578–92.
33. Ames BN. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat Res. 2001;475:7–20.
34. Hirschhorn JN, Lohmueller K, Byrne E. A comprehensive review of genetic association studies. Genet Med. 2002;4:45–61.